Drug Discovery & DDS– category –
-
FDA Grants Breakthrough Therapy Designation to Merck’s Investigational KRAS G12C Inhibitor Calderasib (MK-1084) in Combination with KEYTRUDA for Metastatic NSCLC
BioSpace USA Overview Merck announced that its investigational oral KRAS G12C inhibitor, calderasib (MK-1084), in combination with KEYTRUDA® (pembrolizumab), received FDA Breakthrough Therapy Designation for newly diagnosed metastatic KR... -
Mount Sinai Scientists Discover Hidden Drug-Binding Pocket in Cancer Protein PKMYT1, Highlighting AI Drug Discovery’s Capabilities and Limitations
Mount Sinai - New York USA Overview Mount Sinai scientists discovered a previously overlooked drug-binding pocket in the cancer-related protein PKMYT1. This finding, while highlighting AI drug discovery's capabilities and limitations, op... -
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA)
PMLiVE USA Overview Biogen's investigational antisense oligonucleotide (ASO), salanersen, has received FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA). This designation is based on early clinical data showing impro... -
Janssen’s TECVAYLI® (teclistamab) Achieves Superior Progression-Free and Overall Survival Versus Standard of Care as Early as First Relapse in Multiple Myeloma
Janssen USA Overview New data from the MajesTEC-9 study revealed that TECVAYLI® (teclistamab) demonstrated superior progression-free and overall survival compared to standard of care in patients with relapsed/refractory multiple myeloma ... -
CicadaBio Presents Novel Preclinical Data for CC-18, a GLP-1/ActRII Fusion Protein Designed for Muscle-Preserving Weight Loss, at ADA 2026
Business Wire USA Overview CicadaBio orally presented novel preclinical data for CC-18, a first-in-class GLP-1/ActRII fusion protein designed for muscle-preserving weight loss, at the American Diabetes Association (ADA) 2026 Scientific S... -
Owkin and Sanofi Partner to Co-Develop Next-Generation AI Agents as Part of K Pro Collaboration
Business Wire France Overview Owkin announced a multi-year K Pro collaboration with Sanofi to co-develop next-generation biopharmaceutical AI agents. This partnership builds on their strategic alliance since 2021, focusing on target iden... -
Dana-Farber Cancer Institute Demonstrates Long-Term Efficacy of Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer
Dana-Farber Cancer Institute Newsroom USA Overview The antibody-drug conjugate (ADC), sacituzumab govitecan, demonstrated long-term benefits as a first-line treatment for advanced triple-negative breast cancer (TNBC) compared to standard... -
Oral Peptide Therapeutics Gain Traction in Dermatology, SNAC Technology Offers New Possibilities for Psoriasis Treatment
MedCentral Unknown Overview Oral peptide therapeutics are gaining significant attention in dermatology, particularly for inflammatory skin conditions like psoriasis. Breakthroughs in permeation enhancement technologies, especially oral d... -
Nature Chemical Biology Reports Discovery of Novel E3 Ligase Modulators Opening Path to Intractable Protein Degradation
Nature Chemical Biology USA Overview A new study in Nature Chemical Biology identified novel E3 ligase modulators that can extend the scope of targeted protein degradation (TPD) to a new class of disease-related proteins. This discovery ... -
PMDA Accepts New Drug Application for Japan-Developed Small Molecule Drug ‘XXX-YYY’ for Rare Disease
Japan Times Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted a New Drug Application (NDA) for 'XXX-YYY,' a domestically developed small molecule drug targeting a rare genetic disease. The application ...
